Payment overview · 2025
General Payments
$334,198.29
426 reported records · 26 companies
Healthcare provider profile · identity verified
Dharmesh S. Patel, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · SOUTHAVEN, MS · NPI 1689651036
Verified facts
What the public records show
CMS Open Payments records show Dharmesh S. Patel, MD received $334,198.29 in general payments during 2025 across 426 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 32.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Kerendia, Mounjaro, Nexletol, Ozempic, Verquvo, Wegovy.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 253 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 524 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 326 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Nexletol by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Nexlizet by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 524 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Verquvo by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 603 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 326 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $108,423.94 | 32.4% | 99 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $77,816.60 | 23.3% | 106 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $63,565.81 | 19.0% | 31 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $40,395.52 | 12.1% | 43 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$13,761.69 | 4.1% | 31 | 2025 |
| Ionis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $10,584.45 | 3.2% | 15 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $7,923.50 | 2.4% | 8 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $3,744.10 | 1.1% | 10 | 2025 |
| Regeneron Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $3,571.70 | 1.1% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $2,385.48 | 0.7% | 8 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $298.73 | 0.1% | 6 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $286.00 | 0.1% | 12 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $204.35 | 0.1% | 7 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $200.04 | 0.1% | 10 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $186.14 | 0.1% | 9 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $159.09 | 0.1% | 9 | 2025 |
| Cleerly, Inc. | Unresolved — no canonical attribution shown | $155.89 | 0.1% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $124.53 | 0.0% | 4 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $103.04 | 0.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $75.71 | 0.0% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $62.31 | 0.0% | 3 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $57.00 | 0.0% | 1 | 2025 |
| Impulse Dynamics (USA) Inc. | Unresolved — no canonical attribution shown | $55.59 | 0.0% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $22.64 | 0.0% | 1 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $18.15 | 0.0% | 1 | 2025 |
| Medicure Pharma Inc. | Unresolved — no canonical attribution shown | $16.29 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $243,545.44 | 100 |
| Consulting Fee | $43,995.00 | 12 |
| Travel and Lodging | $36,859.80 | 98 |
| Food and Beverage | $9,798.05 | 216 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $108,423.94 | 99 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $76,581.42 | 104 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $63,478.66 | 28 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $48,098.50 | 46 | 2025 |
Source payment records
|
|||||
| OLEZARSEN Normalized: olezarsen |
Drug | Ionis Pharmaceuticals, Inc. | $9,986.35 | 11 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $8,325.08 | 11 | 2025 |
Source payment records
|
|||||
| EVKEEZA Normalized: evkeeza |
Biological | Regeneron Healthcare Solutions, Inc., Regeneron Pharmaceuticals, Inc. | $3,594.34 | 5 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $2,305.33 | 5 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $1,540.30 | 2 | 2025 |
Source payment records
|
|||||
| TRYNGOLZA Normalized: tryngolza |
Drug | Ionis Pharmaceuticals, Inc. | $571.84 | 3 | 2025 |
Source payment records
|
|||||
| Ambulatory Monitoring & Diagnostics Undivided Normalized: ambulatory monitoring diagnostics undivided |
Device | Philips North America LLC | $266.59 | 11 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $224.10 | 9 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $220.52 | 5 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $204.35 | 7 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $200.04 | 10 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $169.37 | 8 | 2025 |
Source payment records
|
|||||
| THORATEC HEARTMATE 3 LVAS IMPLANT KIT Normalized: thoratec heartmate 3 lvas implant kit |
Device | Abbott Laboratories | $162.17 | 5 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $159.09 | 9 | 2025 |
Source payment records
|
|||||
| Cleerly Ischemia Normalized: cleerly ischemia |
Device | Cleerly, Inc. | $155.89 | 1 | 2025 |
Source payment records
|
|||||
| Cleerly Labs Normalized: cleerly labs |
Device | Cleerly, Inc. | $155.89 | 1 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $136.56 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $92.48 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $62.31 | 3 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $57.00 | 1 | 2025 |
Source payment records
|
|||||
| Optimizer Normalized: optimizer |
Device | Impulse Dynamics (USA) Inc. | $55.59 | 1 | 2025 |
Source payment records
|
|||||
| BodyGuardian Normalized: bodyguardian |
Device | Boston Scientific Corporation | $49.51 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $48.82 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $46.16 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $30.94 | 1 | 2025 |
Source payment records
|
|||||
| AURORA EV-ICD MRI SURESCAN Normalized: aurora ev icd mri surescan |
Device | Medtronic, Inc. | $29.61 | 2 | 2025 |
Source payment records
|
|||||
| CDS - MCT/CEM Monitoring Normalized: cds mct cem monitoring |
Device | Boston Scientific Corporation | $28.86 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $25.50 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.76 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.54 | 1 | 2025 |
Source payment records
|
|||||
| MCOT Normalized: mcot |
Device | Philips North America LLC | $19.41 | 1 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| MICRA Normalized: micra |
Device | Medtronic, Inc. | $17.56 | 1 | 2025 |
Source payment records
|
|||||
| Zypitamag Normalized: zypitamag |
Drug | Medicure Pharma Inc. | $16.29 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 326 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 253 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 524 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 65 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 89 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
42 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
253 | 77 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
65 | 17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
524 | 167 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
326 | 85 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
72 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
524 | 167 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
603 | 156 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
89 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
326 | 85 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1705 | 619 |
| Ezetimibe | Ezetimibe | 1471 | 528 |
| Xarelto | Rivaroxaban | 1243 | 319 |
| Furosemide | Furosemide | 969 | 330 |
| Carvedilol | Carvedilol | 929 | 298 |
| Amlodipine Besylate | Amlodipine Besylate | 902 | 334 |
| Atorvastatin Calcium | Atorvastatin Calcium | 850 | 312 |
| Metoprolol Succinate | Metoprolol Succinate | 841 | 298 |
| Entresto | Sacubitril/Valsartan | 603 | 156 |
| Losartan Potassium | Losartan Potassium | 600 | 208 |
| Repatha Sureclick | Evolocumab | 597 | 118 |
| Potassium Chloride | Potassium Chloride | 558 | 176 |
| Jardiance | Empagliflozin | 524 | 167 |
| Hydralazine Hcl | Hydralazine Hcl | 522 | 167 |
| Spironolactone | Spironolactone | 519 | 184 |
| Clopidogrel | Clopidogrel Bisulfate | 494 | 163 |
| Metoprolol Tartrate | Metoprolol Tartrate | 481 | 166 |
| Lisinopril | Lisinopril | 434 | 155 |
| Amiodarone Hcl | Amiodarone Hcl | 364 | 124 |
| Valsartan | Valsartan | 352 | 127 |
| Eliquis | Apixaban | 326 | 85 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 317 | 98 |
| Clonidine Hcl | Clonidine Hcl | 299 | 156 |
| Sotalol | Sotalol Hcl | 292 | 102 |
| Farxiga | Dapagliflozin Propanediol | 253 | 77 |
| Warfarin Sodium | Warfarin Sodium | 247 | 62 |
| Vascepa | Icosapent Ethyl | 238 | 71 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 232 | 82 |
| Flecainide Acetate | Flecainide Acetate | 225 | 70 |
| Fenofibrate | Fenofibrate | 201 | 58 |
| Nitroglycerin | Nitroglycerin | 201 | 110 |
| Hydrochlorothiazide | Hydrochlorothiazide | 177 | 69 |
| Propranolol Hcl | Propranolol Hcl | 174 | 75 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 152 | 55 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 141 | 58 |
| Ranolazine Er | Ranolazine | 117 | 30 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 115 | 51 |
| Clonidine | Clonidine | 108 | 33 |
| Nebivolol Hcl | Nebivolol Hcl | 105 | 28 |
| Bumetanide | Bumetanide | 100 | 34 |
| Ramipril | Ramipril | 90 | 25 |
| Ozempic | Semaglutide | 89 | 28 |
| Metformin Hcl | Metformin Hcl | 85 | 33 |
| Nexlizet | Bempedoic Acid/Ezetimibe | 72 | 26 |
| Atenolol | Atenolol | 71 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 67 | 21 |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 67 | 18 |
| Midodrine Hcl | Midodrine Hcl | 66 | 29 |
| Sotalol Af | Sotalol Hcl | 66 | 23 |
| Kerendia | Finerenone | 65 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 23 |
| Multaq | Dronedarone Hcl | 54 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 51 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 46 | 19 |
| Brilinta | Ticagrelor | 42 | 12 |
| Omeprazole | Omeprazole | 40 | 13 |
| Praluent Pen | Alirocumab | 38 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 33 | 16 |
| Torsemide | Torsemide | 32 | 14 |
| Isosorbide Dinit-Hydralazine | Isosorbide Dinit/Hydralazine | 31 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 29 | 13 |
| Metformin Hcl Er | Metformin Hcl | 29 | 13 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 28 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 28 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | 13 |
| Sps | Sodium Polystyrene Sulfon/Sorb | 25 | 23 |
| Icosapent Ethyl | Icosapent Ethyl | 24 | 17 |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Nexletol | Bempedoic Acid | 24 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 24 | suppressed |
| Verquvo | Vericiguat | 24 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 22 | suppressed |
| Simvastatin | Simvastatin | 22 | suppressed |
| Amlodipine-Valsartan-Hctz | Amlodipine/Valsartan/Hcthiazid | 21 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 21 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 20 | suppressed |
| Famotidine | Famotidine | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 15 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Livalo | Pitavastatin Calcium | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Wegovy | Semaglutide | 12 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $334,198.29 · 426 records | Bayer Healthcare Pharmaceuticals Inc. | AMVUTTRA, AURORA EV-ICD MRI SURESCAN, AVEIR, Ambulatory Monitoring & Diagnostics Undivided, Barostim Neo System, BodyGuardian, CAMZYOS, CAPVAXIVE, CDS - MCT/CEM Monitoring, COREVALVE EVOLUT R, Cleerly Ischemia, Cleerly Labs, ELIQUIS, EVKEEZA, FARXIGA, FFRct, JARDIANCE, Kerendia, LEQVIO, LOKELMA, LifeVest, MCOT, MICRA, MOUNJARO, NEXLETOL, NURTEC ODT, OLEZARSEN, Optimizer, Ozempic, REPATHA, Rybelsus, SYMPLICITY G3, THORATEC HEARTMATE 3 LVAS IMPLANT KIT, TRYNGOLZA, VERQUVO, WATCHMAN FLX, Wegovy, ZEPBOUND, Zypitamag | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error